UBS analyst Eliana Merle raised the firm’s price target on BridgeBio (BBIO) to $72 from $65 and keeps a Buy rating on the shares. BridgeBio’s Q1 beat highlights the strong launch start of Attruby, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $50 from $46 at BofA
- Cautious Outlook for BridgeBio Pharma Amid Competitive Pressures and Market Uncertainties
- BridgeBio price target raised to $63 from $46 at Piper Sandler
- BridgeBio Pharma’s Attruby Outperforms Expectations, Analyst Raises Price Target to $50
- BridgeBio Pharma Reports Q1 2025 Earnings and Pipeline Progress